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Introduction
After acute coronary syndrome (ACS), various antiplatelet 
agents are used to prevent stent thrombosis, death, and recur-
rent myocardial infarction. The currently available antiplatelet 
agents are clopidogrel, prasugrel, and ticagrelor. The European 
Society of Cardiology guidelines recommend ticagrelor as a first 
choice antiplatelet regimen after ACS (1).
Diffuse alveolar hemorrhage (DAH) is a very rare complica-
tion, but combined with hemoptysis, diffuse lung infiltration, and 
acute respiratory failure, it will be a life-threatening one. Ticagre-
lor and prasugrel have a faster onset and more significant plate-
let inhibition than clopidogrel. Although dyspnea is frequently re-
ported in patients receiving ticagrelor, DAH due to ticagrelor use 
is very rare in the literature (2, 3). Thus, we present two cases of 
antiplatelet-related DAH occurring after ticagrelor therapy.
Case Report
A 57-year-old man was admitted to the emergency service 
with a disturbing chest pain spreading to the back and arms for 
about 4 h. His past medical history was noteworthy for hyperten-
sion, and he was taking 10 mg amlodipin once a day. Electrocardi-
ography revealed ST segment elevation in v1-6 leads and ST seg-
ment depression in d2-3 aVF. After anterior myocardial infarction 
was diagnosed, 300 mg acetylsalicylic acid and 180 mg ticagrelor 
loading doses were given. Coronary angiography was performed, 
and a direct stent to the left anterior descending artery (LAD) was 
successfully implanted. A routine dosage of 100 U/kg unfraction-
ated heparin was given intravenously during the intervention. Due 
to the successful revascularization of the occluded coronary ar-
tery, maintenance anticoagulant treatment was not given after the 
coronary intervention. After follow-up at the coronary intensive 
care unit, the patient developed acute hemoptysis on the 2nd day. 
There was not any obvious reason that can be related to hemop-
tysis. Chest X-ray on the 1st day just after coronary angiography 
was normal (Fig. 1a). However, bilateral diffuse interstitial infiltra-
tion was observed on X-ray and computed tomography (CT) after 
hemoptysis was started (Fig. 1b, 1c). Based on radiological find-
ings, DAH due to ticagrelor emerged as the most obvious reason 
for hemoptysis. Ticagrelor was stopped and continuous oxygen 
inhalation was started at 2 L/min. On the 5th day, hemoptysis was 
stopped, and an improvement in radiological findings was seen on 
control chest X-ray (Fig. 1d). Clopidogrel instead of ticagrelor was 
started as the second antiaggregant therapy, and the patient was 
discharged from the hospital on the 7th day.
The second patient was a 64-year-old man who presented to 
the emergency service with a typical chest pain. His past medical 
history was negligible, and he was not taking any medications. 
Electrocardiography showed anterior myocardial infarction. 
Loading doses of 300 mg acetylsalicylic acid and 180 mg ticagre-
lor were given. Patient was taken into the catheter laboratory, 
and percutaneous coronary intervention to LAD was performed 
successfully. Before stent implantation, 100 U/kg unfractionated 
heparin was given. GpIIa/IIIb inhibitors were not used during or 
after the procedure. Due to the successful revascularization of 
the occluded coronary artery, maintenance anticoagulant treat-
ment was not given after the coronary intervention. Six hours 
after the operation, the patient developed acute hemoptysis. 
A chest X-ray and thoracic CT showed bilateral peribronchial 
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Figure 2. (a) Bilateral peribronchial consolidation after hemoptysis; (b) 
thoracic computed tomography taken during acute respiratory distress; 
(c) improvement of pulmonary infiltrates on the 8th day
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Figure 1. (a) Chest radiograph of the patient before hemoptysis; (b) bi-
lateral peribronchial consolidation after acute respiratory distress; (c) 
thoracic computed tomography taken during acute respiratory distress; 
(d) improvement of pulmonary infiltrates on the 5th day
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In the present case, it is important to consider the differential 
diagnosis of DAH due to antithrombotic treatment. After other 
causes of DAH were excluded, the symptoms of DAH were 
improved in follow-up, and patients were discharged from 
hospital with transitions from ticagrelor to clopidogrel.
References
1. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et 
al.; ESC Scientific Document Group. 2017 ESC focused update on 
dual antiplatelet therapy in coronary artery disease developed in 
collaboration with EACTS. Eur J Cardiothorac Surg 2018; 53: 34-78.
2. Yıldırım F, Kara İ, Okuyan H, Abacı A, Türkoğlu M, Aygencel G. Dif-
fuse alveolar hemorrhage associated with low molecular weight 
heparin and dual anti-platelet therapy after percutaneous coronary 
intervention. Clin Respir J 2017; 11: 1071-3. [CrossRef]
3. Whitmore TJ, O'Shea JP, Starac D, Edwards MG, Waterer GW. A 
case of pulmonary hemorrhage due to drug-induced pneumonitis 
secondary to ticagrelor therapy. Chest 2014; 145: 639-41. [CrossRef]
4. Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest 2010; 137: 
1164-71. [CrossRef]
Address for Correspondence: Dr. Samet Yılmaz, 
Pamukkale Üniversitesi Hastaneleri, 
Kardiyoloji Kliniği, Çamlaralti Mah. Kalp Merkezi No: 7 
Pamukkale/Denizli-Türkiye
Phone: +90 507 305 58 83
E-mail: sametyilmazmd@gmail.com
©Copyright 2018 by Turkish Society of Cardiology - Available online
at www.anatoljcardiol.com
DOI:10.14744/AnatolJCardiol.2018.47776
consolidation (Fig. 2a, 2b). Ticagrelor was stopped and oxygen 
therapy started. On the 2nd day, hemoptysis stopped, and the in-
filtration of the lung areas decreased on chest radiography (Fig. 
1c). The patient was discharged on the 8th day with clopidogrel as 
the second antiplatelet regimen.
Discussion
Alveolar hemorrhage caused by antiplatelet medication is 
a rare complication of ACS. There is only a limited number of 
case reports related to DAH due to ticagrelor in the literature 
before (2, 3). Yıldırım et al. (2) reported a 54-year-old man who 
took ticagrelor therapy due to ACS and developed DAH 4 days 
after ticagrelor use. However, the patient died due to septic shock 
on the 35th day. Whitmore et al. (3) reported a patient who used 
ticagrelor 90 mg BID and aspirin 100 mg daily following stenting. 
Their patient presented with hemoptysis, and CT imaging showed 
bilateral ground-glass opacities consistent with pulmonary 
hemorrhage. They stopped ticagrelor therapy and continued with 
aspirin, and DAH improved (3). These two cases were relatively 
more unstable than our patients after procedure. One of them had 
a cardiac arrest after the admission and died due to sepsis. The 
second one presented to the hospital with pneumonia. However, 
our cases were stable after coronary angiography and developed 
hemoptysis abruptly.
DAH is a life-threatening clinical syndrome characterized by 
common radiographic findings of pulmonary hemorrhage, hypoxic 
respiratory insufficiency, and hemoptysis. The most common 
causes of DAH are pulmonary capillary hypertension, systemic 
vasculitis (microscopic polyangiitis, Wegener granulomatosis), 
and rheumatologic diseases (rheumatoid arthritis, systemic 
lupus erythematosus). The diagnosis of DAH is based on clinical, 
radiographic, bronchoscopic, and pathologic examination. 
Sometimes, the diagnosis of DAH is made by exclusion of other 
reasons related to dyspnea. DAH is frequently clinically confused 
with acute pulmonary edema and may lead to false diagnosis.
The most probable cause of DAH in our cases was the 
antiplatelet action of ticagrelor. Patients were discharged from 
hospital with clopidogrel, and there was no bleeding event after 
discharge. Although clopidogrel also has an antiplatelet effect, 
ticagrelor has a stronger effect on platelet aggregation. This 
may be the explanation of hemoptysis with ticagrelor but not 
clopidogrel. Another explanation may be that ticagrelor induced 
pneumonia due to drug hypersensitivity. Histopathologic diagnosis 
is required for demonstrating this drug reaction. However, biopsy 
was not done in our patients. Therefore, exclusion of this cause 
is not possible at this time.
The proper treatment of DAH depends on the underlying 
reason. Immunosuppressive treatment is the basis of treatment 
in patients with DAH associated with systemic vasculitis and 
rheumatic diseases (4). However, there is no definitive treatment 
algorithm for DAH due to antiplatelet agents. First, all drugs with 
antiplatelet or antithrombotic effect should be cut and reversed 
as soon as possible. Second, oxygen, bronchodilators, intubation, 
and mechanical ventilation should be given.
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Introduction
Once accepted as a benign phenomenon, electrocardio-
graphic early repolarization pattern is now considered to have 
significant clinical importance. Haïssaguerre et al. (1) were first 
to describe the possible association between early repolariza-
tion pattern and idiopathic ventricular fibrillation. Since then, 
numerous studies have documented the clinical association be-
tween early repolarization pattern and future arrhythmic events. 
Due to different definitions, the prevalence of early repolarization 
pattern varies widely between 2% and 31% (2). The 2015 Europe-
an Society of Cardiology Guidelines for the management of ven-
tricular arrhythmias and the prevention of sudden cardiac death 
recommend that early repolarization syndrome (ERS) should be 
diagnosed only in patients with early repolarization pattern on 
electrocardiography (ECG) and a history of resuscitated cardiac 
